We are live on ! Find out more

Revvity

RVTY

Market cap $15.6B

140.19 USD

+11.70

9.11%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

140.02

-0.17

0.12%

1 day

9.11%

5 days

11.47%

1 month

20.68%

3 months

39.42%

6 months

62.11%

Year to date

42.83%

1 year

66.89%

5 years

-24.97%

10 years

163.71%

About: Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Employees: 11,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 41.9%

Neutral 58.1%

Negative 0%

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment Research

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery

Zacks Investment Research

Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including.

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Zacks Investment Research

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Zacks Investment Research

What Makes Revvity (RVTY) a New Buy Stock

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Revvity (RVTY) a New Buy Stock

Zacks Investment Research

Is the Options Market Predicting a Spike in Revvity Stock?

Investors need to pay close attention to RVTY stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Revvity Stock?

Zacks Investment Research

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

See News Rankings

Price charts implemented using Lightweight Charts™